Depression is one of the most widespread and debilitating mental disorders globally, with a significant impact on patients' quality of life and a considerable economic burden on healthcare systems. Despite the availability of numerous antidepressant medications, current therapies have notable limitations, such as variable efficacy, delayed onset of therapeutic effects, and a range of side effects that often hinder treatment adherence. In light of these challenges, the urgent need to develop new therapeutic approaches has become evident. In this context, psilocybin is attracting growing interest for its innovative therapeutic potential in the treatment of depression. This thesis explores the emerging role of psilocybin as a potential treatment, beginning with a general overview and an introduction to its neurobiological mechanisms of action. The thesis then examines the use of psilocybin in various clinical trials, where the combination of the compound's administration and supportive psychotherapy has proven crucial to optimizing therapeutic outcomes and minimizing risks. Psilocybin could represent a new frontier in the treatment of depression, especially for patients resistant to traditional therapies. However, future research will need to address several challenges to confirm these results and establish safe and effective clinical guidelines.
La depressione è uno dei disturbi mentali più diffusi e debilitanti a livello globale, con un impatto significativo sulla qualità della vita dei pazienti e un notevole peso economico per i sistemi sanitari. Nonostante la disponibilità di numerosi farmaci antidepressivi, le terapie attuali presentano limiti significativi, come un’efficacia variabile, un’ insorgenza ritardata degli effetti terapeutici e una serie di effetti collaterali che spesso compromettono l’aderenza al trattamento.Di fronte a questa situazione, emerge con urgenza la necessità di sviluppare nuovi approcci terapeutici. In questo contesto, la psilocibina sta attirando un crescente interesse per il suo potenziale terapeutico innovativo nel trattamento della depressione. Questa tesi esplora il ruolo emergente della psilocibina come potenziale trattamento, iniziando con una panoramica generale e un'introduzione ai suoi meccanismi d'azione neurobiologici. Successivamente, la tesi analizza l'uso della psilocibina in diversi trial clinici, dove l'associazione tra somministrazione del composto e psicoterapia di supporto si è dimostrata fondamentale per ottimizzare i risultati terapeutici e minimizzare i rischi. La psilocibina potrebbe rappresentare una nuova frontiera nel trattamento della depressione, specialmente per i pazienti resistenti alle terapie tradizionali. Tuttavia, la ricerca futura dovrà affrontare diverse sfide per confermare questi risultati e per stabilire linee guida cliniche sicure ed efficaci.
NUOVE PROSPETTIVE TERAPEUTICHE PER LA DEPRESSIONE: IL RUOLO DELLA PSILOCIBINA
ANDREATTA, ELENA
2023/2024
Abstract
Depression is one of the most widespread and debilitating mental disorders globally, with a significant impact on patients' quality of life and a considerable economic burden on healthcare systems. Despite the availability of numerous antidepressant medications, current therapies have notable limitations, such as variable efficacy, delayed onset of therapeutic effects, and a range of side effects that often hinder treatment adherence. In light of these challenges, the urgent need to develop new therapeutic approaches has become evident. In this context, psilocybin is attracting growing interest for its innovative therapeutic potential in the treatment of depression. This thesis explores the emerging role of psilocybin as a potential treatment, beginning with a general overview and an introduction to its neurobiological mechanisms of action. The thesis then examines the use of psilocybin in various clinical trials, where the combination of the compound's administration and supportive psychotherapy has proven crucial to optimizing therapeutic outcomes and minimizing risks. Psilocybin could represent a new frontier in the treatment of depression, especially for patients resistant to traditional therapies. However, future research will need to address several challenges to confirm these results and establish safe and effective clinical guidelines.File | Dimensione | Formato | |
---|---|---|---|
Andreatta_Elena.pdf
accesso aperto
Dimensione
1.86 MB
Formato
Adobe PDF
|
1.86 MB | Adobe PDF | Visualizza/Apri |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/80589